Posted by Michael Wonder on 30 Jun 2016
pERC issues final recommendation for cobimetinib hemifumarate (Cotellic)
30 June 2016 - The Pan Canadian Expert Review Committee has issued a final recommendation on the use of cobimetinib hemifumarate (Cotellic) in combination with vemurafenib (Zelboraf).
The Committee has recommended the use of cobimetinib hemifumarate in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanome with a BRAF V600 mutation on the proviso that its cost-effectiveness be improved to an acceptable level.
